Cyclosporin A (CsA) has been shown to protect against ischaemia/reperfusion injury presumably by its inhibition of mitochondrial permeability transition pore opening through cyclophilin D inhibition. We examine if CsA cardioprotection involves a cell-volume regulatory mechanism.
Introduction
Permanent opening of the mitochondrial permeability transition pore (MPTP) is considered to play a fundamental role in the transition from reversible to irreversible injury of cardiomyocytes when exposed to a prolonged period of ischaemia followed by reperfusion. 1 The MPTP, when open, allows solutes up to 1.5 kDa to pass freely across both the outer and inner mitochondrial membranes resulting in a collapse of the proton electrochemical gradient (DCm) between the inner and outer membranes and an influx of osmotically obligated water resulting in mitochondrial swelling with stretching of the mitochondrial membranes to the point where the outer membrane breaks. In this situation, there is a loss of mitochondrial ATP production and, moreover, a conversion to ATP consumption. If sufficient numbers of mitochondria are ruptured, ATP consumption in damaged mitochondria dominates over ATP production by intact mitochondria resulting in profound cardiomyocyte ATP depletion, cell swelling, and ultimately cell membrane rupture, i.e. necrotic cell death. 1 A consensus has developed that the MPTP is a key end effector of both ischaemic preconditioning (IPC) and post-conditioning. 2 It is well recognized that opening of the MPTP occurs on reperfusion following a long period of ischaemia as demonstrated by Halestrap et al. 3 Cyclosporin A (CsA) is the prototypic inhibitor of MPTP opening. This inhibiting effect is attributed to the interaction of CsA with the mitochondrial matrix protein cyclophilin D. 4, 5 Because CsA can also interact with other proteins outside the mitochondria, other effects on cellular function must be taken into account when interpreting the effects of CsA on cell survival following ischaemia/reperfusion. In normoxic, healthy, non-cardiac cells, CsA stimulates Cl 2 efflux. 6, 7 Cl 2 is a key anion in cell-volume regulation and we have shown that IPC enhances cell-volume regulation in cardiomyocytes, triggering Cl 2 efflux, 8 and that blocking cell-volume regulation during IPC by inhibiting Cl 2 transport across the cell membrane IPC protection is blocked. 8 -10 Therefore, it is conceivable that CsA protection may result, at least in part, from an effect of CsA on cell-volume regulation reflected in chloride-ion transport across the sarcolemma. In this study, using mature rabbit cardiomyocytes in culture, we demonstrate that CsA, in addition to inhibiting MPTP opening, enhances the ability of the cardiomyocytes to regulate cell volume by Cl 2 channel activation, as demonstrated by measuring Cl 2 efflux through fluorescence of the indicator SPQ and measuring cardiomyocyte swelling under osmotic stress. Moreover, the protection of CsA against cardiomyocyte ischaemia/reperfusion necrosis is completely blocked by Cl 2 channel inhibition indicating that CsA protects against necrosis at least in part through a volume regulatory mechanism, not simply by acting directly on cyclophilin D to inhibit MPTP opening.
Methods
All experiments performed in animals conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011). We obtained animal protocol approval from the Animal Care Committee at our institution for the use of donor rabbits and experimental protocols established for these studies (Animal Protocol #1000012181). All chemicals used in these studies were obtained from Sigma-Aldrich (Canada) unless stated otherwise.
Preparation of cardiomyocyte primary cultures
Ventricular cardiomyocytes were first isolated form New Zealand adult white rabbit (3-3.5 kg) hearts by enzymatic digestion as described previously (see Supplementary material online for details). 8, 9 After isolation, cardiomyocytes were placed either on circular laminin-coated glass slides (35 mm diameter) (Bioptechs Inc., USA) that were already immersed in culture medium 199 with Earle's salts (Gibco, Canada) and supplemented with 10% FBS, 10 mM cytosine b-D-arabinofuranoside, 100 IU/mL penicillin, 100 mg/mL streptomycin, and 0.08 mg/mL gentamicin in 60 mm diameter Petri dishes (for the SPQ studies), or on bottom glass 35 mm diameter Petri dishes (for the cell death and cell-volume measurements), and cultured for 48 h. Culture medium was exchanged once for freshly prepared medium after the first 24 h in culture. Only cellculture plates with .75% rod-shaped viable cardiomyocytes were used in these studies.
Experimental protocols
After 48 h in culture, cardiomyocytes were stabilized first in culture medium 199 supplemented with 0.1% BSA for 30 min before initiating any treatment when used to either study CsA cardioprotection against necrotic cell death, assess the ability of CsA to influence Cl 2 ion movement across the sarcolemma, or perform the concentration-response for CsA to inhibit the opening of the MPTP in vitro in viable ventricular cardiomyocytes. ) heating chamber (Bioptechs Inc., USA) and incubated in medium 199 supplemented with 5% FBS for 10 min to stabilize prior to any intervention. SPQ fluorescence was excited at 350 nm using UV light, and fluorescence, emitted at 460 nm, was recorded using an A4 filter cube (360 + 40 nm excitation range and 470 + 40 nm emission range) on the stage of an inverted Leica DMIRE2 microscope (Leica Microsystems Inc., Canada). Cardiomyocyte fluorescence images were acquired before CsA (200 nM) or DMSO (vehicle) treatment (with or without concurrent administration of the Cl 2 channel blocker IAA-94 (50 mM), after 10 min
Cell-viability studies
CsA/DMSO (+IAA-94) treatment and following 10 min of washout (+IAA-94) and, subsequently, SPQ fluorescence intensities were measured using the NIH Image software (US NIH, USA). Only rod-shaped, well into focus, and non-overlapping cardiomyocytes were used.
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Mitochondrial trans-membrane potential studies
To study the effect of CsA on MPTP, we monitored the changes in mitochondrial trans-membrane potential (DC(m)) using the sensor dye 5,5
′ -tetraethylbenzimi-dazolylcarbocyanine iodide (JC-1, Invitrogen, USA) as previously described.
14 After an initial stabilization in medium 199 supplemented with 0.1%BSA, cardiomyocytes were loaded with JC-1 dye (5 mM) for 20 min (at 378C in an incubator). JC-1 is a cationic dye which exhibits trans-membrane potential-dependent accumulation in mitochondria, indicated by a fluorescence emission shift from green ( 525 nm) to red ( 590 nm). Consequently, mitochondrial depolarization is indicated by a decrease in the red/green fluorescence intensity ratio. The inter-membrane potential-sensitive colour shift is due to concentration-dependent formation of red fluorescent J-aggregates. After loading, cardiomyocytes were stabilized for an additional 10 min on the stage of a Quorum spinning disk confocal Leica DMIRE2 microscope equipped with a temperature (378C) control chamber. Next, cardiomyocytes were either treated with CsA ( 
Measurement of changes in cell volume during hypo-osmotic stress
To establish a functional relationship between the effect of CsA on SPQ fluorescence (changes in intracellular Cl 2 concentration) and its ability to modify cell-volume regulation in normal oxygenated cardiomyocytes, we measured the changes in cell volume (to determine peak cell swelling) before and during exposure to hypo-osmotic stress using a method we have previously described. 9, 16 Briefly, images of randomly selected microscopic field are acquired using a computer-controlled motorized x-y stage of a microscope. Then, cardiomyocyte surface areas were traced using a computer software (Volocity, Perkin Elmer Inc.). Subsequently, data were adjusted following application of a correction factor to estimate the % change in cell volume. 16 
Statistical analysis
All cardiomyocyte fluorescence data were first analysed for normal distribution (Kolmogorov -Smirnoff test) and equality of variance (F-test). ANOVA analysis followed by Scheffe's post-hoc test was performed to determine significant differences (P , 0.05) among groups and between two groups, respectively. Where the criteria for parametric analysis were not met, we performed a non-parametric analysis (Kruskal -Wallis followed by Mann-Whitney U) to determine whether a significant difference (P , 0.05) existed between the two groups. Data are expressed as mean + SEM.
Results
We first established the concentration of valinomycin that produces consistent and profound depolarization of the mitochondrial transmembrane potential (DCm) in 48 h cultured rabbit cardiomyocytes as measured by the degree of reduction in JC-1 fluorescence ratio (red/green fluorescence). As observed in Figure 1A , while 0. Taken together, these results suggest that 200 nM CsA protects cardiomyocytes against ischaemia/reperfusion-induced cell death through at least two mechanisms, by inhibiting MPTP opening and by enhancing cell-volume regulation in cardiomyocytes.
Discussion
In this study, we demonstrate for the first time that CsA (200 nM) treatment induces an efflux of Cl 2 from cardiomyocytes, measured by changes in SPQ fluorescence, that is nearly equal in magnitude to the efflux of Cl 2 produced by either IPC or the adenosine receptor agonist N6-2-(4-aminophenyl)ethyladenosine (APNEA) 9 and results in an enhanced cell-volume regulatory response, as indicated by the ability of CsA-treated cardiomyocytes to resist a 200 mOsm hypo-osmotic stress without developing a substantial increase in cell volume (cell swelling) while, in separate experiments, rendering cardiomyocytes resistant to a dissipation of the mitochondrial transmembrane potential (DCm) induced by either valinomycin or SI and SR, and protected against cell necrosis caused by exposure of the cardiomyocytes to 75 min SI followed by 60 min of SR. Moreover, the reduction in cardiomyocyte swelling in response to hypo-osmotic stress, reflecting enhanced cell-volume regulation, and the substantial reduction in necrosis to ischaemia/reperfusion, were both substantially blocked by inhibiting Cl 2 channels with IAA-94 at 50 mM, a concentration which did not affect the DCm as monitored by the sensor dye JC-1. Our results clearly indicate that the CsA protects against cardiomyocyte necrosis at least in part through a cell-volume regulatory mechanism and not simply by acting directly on cyclophilin D to inhibit MPTP opening. Cell swelling activates a variety of transport pathways that result in a net efflux of K + , Cl
2
, H + organic anions, and organic osmolytes with individual K + and Cl 2 channels as the key contributors. We were the first to suggest a role for enhanced cell-volume regulation in the cardioprotection of IPC and propose that Cl 2 channel activity is an end-effector of IPC. 10 We have demonstrated that a hypo-osmotic stress, which triggers cardiomyocyte swelling followed by an RVD response back towards initial cell volume under normoxic conditions, mimics IPC in protecting cardiomyocytes from necrosis under conditions simulating ischaemia/reperfusion. 16 Moreover, we established that ion channels which remove Cl 2 and K + from cardiomyocytes are necessary for both volume control under normal normoxic conditions and in IPC cardioprotection which causes a marked reduction in ischaemic cell swelling. 9, 11, 16 The mechanism(s) of Cl 2 channel activation by CsA is unknown and at least three types of Cl 2 channels might be involved in the efflux of chloride ions observed in our studies with 200 nM CsA: (i) the swell-activated Cl 2 channel (I CL-SWELL ) which appears to underlie the ClC-3 channel; 17 -19 (ii) the ClC-2 channel; 20 and (iii) the CFTR channel which has been shown to play a key role in IPC. 21 In addition, it is conceivable that other Cl 2 channels (e.g. Ca 2+ -activated Cl 2 channel) and transporters (e.g. Na + -K + -Cl 2 co-transporter) might also contribute to the Cl 2 efflux induced by CsA. Understanding how CsA triggers the activation of some of these Cl 2 channels is of interest but beyond the scope of this manuscript. Although we have not measured K + efflux in response to CsA treatment, it is conceivable that a potassium efflux also occurs. Efflux of positively charged ions such as K + must follow Cl 2 efflux for the sarcolemmal membrane to maintain its electrochemical gradient and hence its resting membrane potential. During ischaemia, the only two K + channels that remain operationally active to export K + are the ATP-sensitive potassium channel and the IK1 potassium channel. We have previously demonstrated that pharmacological blockade of ATP-sensitive potassium channels with the specific blocker HMR1098 did not affect the protection by IPC, 11 indicating that the IK1 channel is the predominant K + carrier channel that functions during ischaemia to export K + out of cells to counter-balance the efflux of Cl 2 in response to IPC. In the present studies, experiments on Cl 2 efflux were performed under oxygenated conditions. Therefore, K + channels other than IK1
could have balanced the CsA-induced Cl 2 efflux. Also, Na + transport could have been involved. Determining channel involvement when a CsA-induced efflux of Cl 2 under normoxic conditions occurs is beyond the scope of the present manuscript and remains to be elucidated. During ischaemia, metabolites such as lactate accumulate in cardiomyocytes, thus increasing osmolarity. The resulting osmotic gradient between the intracellular and extracellular milieu draws osmotically obligated water into the cardiomyocyte causing cell swelling. This osmotic load has been estimated to be 60 mOsm by the time of transition to irreversible ischaemic injury of the myocardium. 22 We have demonstrated that IPC causes a net Cl 2 efflux of 30 mM in cardiomyocytes, 8 about half the 60 mOsm gradient, with the other half presumably coming from cations (e.g. K + ) essential for charge balance. Cardiomyocyte swelling is limited during ischaemia because osmolytes accumulate in the extracellular space, tending to equilibrate with those in cardiomyocytes. However, on reperfusion, osmolytes which have accumulated during ischaemia are washed out of the extracellular space. More water enters the cell and further cell swelling may rupture cell membranes already weakened by proteases and lipases producing oncotic cell death (necrosis). We have hypothesized that IPC activation of enhanced cardiomyocyte volume regulation, with attendant Cl 2 efflux, protects in part through mitigation of cardiomyocyte swelling during ischaemia/ reperfusion which, in turn, reduces cell-membrane rupture and, thus, cell death. 9 A degree of swelling which normoxic cardiomyocytes can tolerate will rupture injured cell membranes of hypoxic/ischaemic cardiomyocytes. Volume regulation and cyclosporin a cardioprotection
We recognize that the primary culture adult cardiomyocyte model of the SI/SR, used in these studies, has inherent limitations. A long ischaemic episode is simulated by a combination of severe hypoxia (100% nitrogen environment), glucose deprivation (replacement of glucose by osmotically equivalent 2-deoxy glucose), and exposing cardiomyocytes to an extracellular media environment similar to the interstitium of the myocardium following prolonged ischaemia, with pH adjusted to 6.5, and 20 mM of lactate and 12 mM of KCl added. This ischaemic cell-culture model lacks a tight restriction on water as the cardiomyocytes are immersed in an almost infinite ratio of bathing medium compared with collective volume of the cardiomyocytes. This is in contrast to the freshly isolated cardiomyocyte model that restricts water in the surrounding media during SI by pelleting cells under an oil layer to restrict the diffusion of oxygen, as we have reviewed. 9, 23 However, while the pelleted cardiomyocyte model does well-simulate no-flow ischaemia, it does not allow the repeated visualization in the same cardiomyocyte over time the open/closed state of the MPTP using DCm measurements. This requires cardiomyocyte immobilization by attachment to the cellculture dish. SI in our cell-culture model more closely resembles low-flow ischaemia rather than no-flow ischaemia in the intact heart in vivo. However, using this SI approach in primary cultured cardiomyocytes, we have been able to demonstrate that 30 min of SI can induce significant cardiomyocyte swelling, 9 implying that accumulation of metabolic-by-products is still occurring inside the cardiomyocytes increasing the intracellular osmolarity, as in the intact organ, and, more importantly, that pre-conditioning with ischaemia, which also causes an efflux of Cl
, not only prevents ischaemic cell swelling but also shrinks the cardiomyocytes slightly, and protects against necrosis produced from SI/SR. 9 The importance of enhanced cell-volume regulation in protecting cardiomyocytes from ischaemia/reperfusion necrosis, including in CsA-mediated cardioprotection as determined in the present study, should not be considered to suggest that the MPTP open/closed state is not of importance in the outcome of cardiomyocyte necrosis. There is a biophysical linkage between mitochondrial volume and cell volume. Mitochondrial swelling requires an influx of cytosolic water and electrolytes which concentrates cytosolic proteins, increasing cytosolic colloid osmotic pressure which, in turn, is compensated by an influx of water and electrolytes from the extracellular space, as reviewed by Kaasik et al. 24 Furthermore, reduced mitochondrial volume strongly favours the closed state of the MPTP, greatly reducing its opening sensitivity to calcium ions. 25 Thus, there is an osmotic link between cell volume and MPTP opening with the implication that improved cell-volume regulation (i.e. less cardiomyocyte swelling) and reduced MPTP opening during ischaemia/reperfusion go together. On this basis, we propose that protection against cardiomyocyte necrosis under conditions of ischaemia/reperfusion operates through the biophysically interlinked combination of two end-effector mechanisms: enhanced cell-volume regulation, achieved by activation of specific sarcolemmal chloride-ion channels, and inhibition of permanent MPTP opening. (Figure 4) , IAA-94 blockade of CsA-induced cardioprotection against necrosis is unlikely to be the result of IAA-94 interacting with proteins associated with maintaining or modulating DCm, including cyclophilin D. Therefore, blockade of cardioprotection by IAA-94 was not operating through a direct effect of IAA-94 on the MPTP. Valinomycin induced a rapid DCm drop as measured by JC-1 in our cardiomyocytes. We used the valinomycin-induced DCm drop in the cardiomyocytes as an index of opening of the MPTP. We recognize that the valinomycin-induced collapse of the DCm is distinct from MPTP opening itself. However, in our concentration -response studies ( Figure 1A and B), we demonstrated that CsA did substantially inhibit the effect of valinomycin, administered either at 200 or 400 nM, on DCm in our isolated cardiomyocytes. This is consistent with the known effect of CsA at 200 nM to inhibit MPTP opening in cardiomyocytes. 27 CsA is well established at 200-400 nM to protect against necrosis from SI/SR in cardiomyocytes. 28 Furthermore, the inhibitory effect of CsA on valinomycin-induced collapse of DCm cannot be attributed to CsA causing accumulation of the dye, as previously shown for tetramethylrhodamine methyl ester (TMRM), 29 because the JC-1 is a ratiometric dye and the changes in DCm are based on the measurements of red/green fluorescence ratios. This feature makes JC-1 dye ideal for use in measuring the changes in DCm during SI and SR in primary cultured cardiomyocytes. We have recently demonstrated that CsA at 200 nM inhibits MPTP opening, as assessed by DCm measurement by JC-1, induced by ischaemia/reperfusion injury (during SI/SR) in our cultured cardiomyocyte model ( Figure 3) . The findings of the present study open the way for more comprehensive investigation examining the interaction of cell volume, mitochondrial volume, and the MPTP in the transition of cardiomyocytes from reversible to irreversible injury in the context of ischaemia and reperfusion.
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